Quince Therapeutics (Quince Therapeutics) Beta : 1.44 (As of May. 15, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Quince Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-15), Quince Therapeutics's Beta is 1.44.

Quince Therapeutics Beta Historical Data

The historical data trend for Quince Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quince Therapeutics Beta Chart

Quince Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beta

Get a 7-Day Free Trial

0.47

1.43

Quince Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beta	Get a 7-Day Free Trial															0.95	1.14	1.23	1.43	1.51

Competitive Comparison of Quince Therapeutics's Beta

For the Biotechnology subindustry, Quince Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quince Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quince Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Quince Therapeutics's Beta falls into.

Quince Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Quince Therapeutics (NAS:QNCX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Quince Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Quince Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Quince Therapeutics (Quince Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quince Therapeutics Inc (NAS:QNCX) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

N/A

Address

601 Gateway Boulevard, Suite 1250, South San Francisco, CA, USA, 94080

Website

https://www.quincetx.com

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Executives

David Lamond	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Guenter Janhofer	officer: Chief Scientific Officer	601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Charles S. Ryan	officer: President	C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Dirk Thye	director, officer: Chief Executive Officer	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Brendan Hannah	officer: Chief Business Officer	269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Margaret Mcloughlin	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Ted Monohon	officer: Chief Accounting Officer	C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107
June Bray	director	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Caryn Gordon Mcdowell	officer: Chief Legal & Adm. Officer	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Karen L. Smith	officer: Chief Medical Officer	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Philip S Low	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Marwan Sabbagh	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Stephen S. Dominy	director, officer: Chief Scientific Officer	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105
Christopher P. Lowe	officer: Chief Financial Officer	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258